Bristol-Myers, J&J, Merck, AbbVie aim at Gilead in hepatitis C battle
This article was originally published in Scrip
Executive Summary
Gilead Sciences heads into a major medical meeting this week as the company to beat in an intense competition to develop better hepatitis C treatments.